Literature DB >> 15860278

Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase.

Baptiste Vergnes1, Laurent Vanhille, Ali Ouaissi, Denis Sereno.   

Abstract

Silent information regulator 2 (SIR2) proteins are NAD-dependant deacetylases found in organisms ranging from bacteria to human. In eukaryotes, these proteins are involved in many biological processes including transcriptional repression, metabolism, ageing, or apoptosis. Here, we have shown that Sirtinol, a commercially available inhibitor of SIR2 deacetylases, significantly inhibits the in vitro proliferation of Leishmania infantum axenic amastigotes in a dose-dependent manner. This activity is stage specific since sirtinol did not affect the in vitro growth of parasite promastigotes. Growth arrest in amastigotes is associated with genomic DNA fragmentation, a process reminiscent of apoptosis. Interestingly parasites carrying extra copies of the LmSIR2 gene were less susceptible to the sirtinol mediated cell death. Altogether, these results constitute novel evidences that Leishmania SIR2 proteins play a role in the control of the parasite apoptotic phenomenon.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860278     DOI: 10.1016/j.actatropica.2005.03.004

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  15 in total

Review 1.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  Sirtuin activators and inhibitors.

Authors:  José M Villalba; Francisco J Alcaín
Journal:  Biofactors       Date:  2012-06-25       Impact factor: 6.113

3.  Structural analysis of trypanosomal sirtuin: an insight for selective drug design.

Authors:  Simranjeet Kaur; Amol V Shivange; Nilanjan Roy
Journal:  Mol Divers       Date:  2009-04-29       Impact factor: 2.943

4.  The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.

Authors:  Quaovi Sodji; Vishal Patil; Surendra Jain; James R Kornacki; Milan Mrksich; Babu L Tekwani; Adegboyega K Oyelere
Journal:  Bioorg Med Chem Lett       Date:  2014-09-04       Impact factor: 2.823

Review 5.  Toxoplasma histone acetylation remodelers as novel drug targets.

Authors:  Laura Vanagas; Victoria Jeffers; Silvina S Bogado; Maria C Dalmasso; William J Sullivan; Sergio O Angel
Journal:  Expert Rev Anti Infect Ther       Date:  2012-10       Impact factor: 5.091

6.  Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death.

Authors:  Despina Smirlis; Michael Duszenko; Antonio Jiménez Ruiz; Effie Scoulica; Patrick Bastien; Nicolas Fasel; Ketty Soteriadou
Journal:  Parasit Vectors       Date:  2010-11-17       Impact factor: 3.876

Review 7.  Visceral leishmaniasis: experimental models for drug discovery.

Authors:  Suman Gupta
Journal:  Indian J Med Res       Date:  2011-01       Impact factor: 2.375

8.  Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.

Authors:  Mehdi Ouaissi; Ali Ouaissi
Journal:  J Biomed Biotechnol       Date:  2006

Review 9.  Sirtuins of parasitic protozoa: in search of function(s).

Authors:  Agnieszka A Religa; Andrew P Waters
Journal:  Mol Biochem Parasitol       Date:  2012-08-10       Impact factor: 1.759

Review 10.  Lysine acetylation: elucidating the components of an emerging global signaling pathway in trypanosomes.

Authors:  Victoria Lucia Alonso; Esteban Carlos Serra
Journal:  J Biomed Biotechnol       Date:  2012-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.